A comparison of the efficacy and tolerability of the PCSK9 inhibitors, Alirocumab and evolocumab, in routine lipid clinic practice

Abstract

Aim: The UK NICE Technology Advice Guidance published in June 2016 recommends alirocumab and evolocumab use in Familial Hypercholesterolaemia and secondary prevention at different low density lipoprotein – cholesterol (LDL-C) thresholds following the use of maximum tolerated oral lipid lowering agents. The suggested LDL-C cut-offs are 5.0mmol/l, 4.0mmol/l and 3.5mmol/l for primary prevention FH, single vascular bed secondary prevention and multiple vascular bed secondary prevention respectively.